Q4 2024 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Teva Pharmaceutical Industries Ltd (TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong performance across its innovative, generics, and API businesses.
- AUSTEDO sales grew by 34%, reaching $1.7 billion, with strong TRx growth and a significant contribution from international markets.
- AJOVY sales increased by 18%, surpassing $0.5 billion, with market share gains across all regions.
- The company achieved eight consecutive quarters of growth, demonstrating consistent performance and progress in its Pivot to Growth strategy.
- Teva's credit ratings improved, with all major agencies upgrading their outlook, reflecting enhanced growth prospects and a stronger balance sheet.
- Teva Pharmaceutical Industries Ltd (TEVA) reported a GAAP operating loss of $29 million in Q4 2024, primarily due to a goodwill impairment charge related to its API business.
- The company's non-GAAP gross profit margin decreased to 54.8% in Q4 2024, impacted by foreign exchange headwinds and higher operating expenses.
- Teva's free cash flow guidance for 2025 is lower than 2024, primarily due to higher legal settlement outflows and adjustments in accounts receivable securitization.
- The company faces potential headwinds from the Inflation Reduction Act in the US, which could impact its innovative product portfolio.
- Teva's operating margin guidance for 2025 indicates a compression, raising concerns about achieving its long-term target of 30% by 2027.
Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. (Operator Instructions)
And I hand it over to your host, Chris Stevo, SVP, Investor Relations. Please go ahead.
Thank you, Alex. Good morning and good afternoon, everyone. I'd like to remind you briefly that we're going to be making forward-looking statements on this call. Any statements we make are as of today only, and we undertake no obligation to update these statements afterwards. And if you have any questions about forward-looking statements, or other risk disclosures, please see our SEC filings under Forms 10-K and 10-Q.
And with that, let me turn it over to Richard.
Thank you, Chris, and good morning, good afternoon, everybody. Thank you for dialing in for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
